Table 4.
Univariate and multivariate logistic regression analyses of factors associated with fibrosis (stages 3 and 4) in HIV-HCV coinfected patients
| Factor | Univariate analysis, OR (95% CI) | p Value | Multivariate analysis, OR (95%CI) | p Value |
| Sex | ||||
| Female (ref) | 1 | |||
| Male | 0.79 (0.24–2.60) | 0.70 | — | |
| Age at HCV infection (y) | ||||
| ⩽22 (ref) | 1 | |||
| >22 | 0.94 (0.31–2.83) | 0.91 | — | |
| Duration of HCV (y) | ||||
| ⩽15 (ref) | 1 | |||
| >15 | 3.07 (1.01–9.25) | 0.04 | 1.84 (0.45–7.41) | 0.39 |
| Alcohol (units/week) | ||||
| ⩽20 (ref) | 1 | |||
| >20 | 2.96 (0.77–11.30) | 0.11 | 3.67 (0.79–17.05) | 0.07 |
| Route of HCV transmission | ||||
| Transfusion (ref) | 1 | |||
| IDU | 2.3 (0.60–8.79) | 0.22 | — | |
| ALT (IU/l) | 1 | |||
| ⩽80 (ref) | ||||
| >80 | 4.44 (1.36–14.46) | 0.01 | 3.71 (0.90–15.27) | 0.06 |
| Genotype | ||||
| Other (ref) | 1 | |||
| Genotype 1 | 2.66 (0.19–36.75) | 0.46 | — | |
| CD4 count at liver biopsy (/mm3) | ||||
| >250 (ref) | 1 | |||
| ⩽250 | 3.57 (1.13–11.25) | 0.03 | 5.36 (1.26–22.79) | 0.02 |
| HIV load at liver biopsy (copies/ml) | ||||
| ⩽400 (ref) | 1 | |||
| >400 | 0.99 (0.32–0.08) | 0.99 | — | |
| Antiretroviral treatment* | ||||
| Never (ref) | 1 | |||
| Ever | 0.82 (0.24–2.75) | 0.76 | — | |
HIV, human immunodeficiency virus; HCV, hepatitis C virus; HAART, highly active antiretroviral therapy; IDU, injecting drug use; ALT, alanine aminotransferase; OR, odds ratio.
*The use of HAART, or type of HAART regimens (protease inhibitor based regimens v non-nucleoside reverse transcriptase inhibitor based regimens) were also not associated with fibrosis stage.